What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

Molly M. Foote, Milo Careaga, Robert F Berman

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. Conclusions: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.

Original languageEnglish (US)
Pages (from-to)960-972
Number of pages13
JournalClinical Neuropsychologist
Volume30
Issue number6
DOIs
StatePublished - Aug 17 2016

Fingerprint

Trinucleotide Repeat Expansion
Inborn Genetic Diseases
Poisons
Intellectual Disability
Neurodegenerative Diseases
Pathology
Peptides
Fragile X Tremor Ataxia Syndrome
Syndrome
Mouse
Research
Genes
Carrier
Therapeutics
Late Onset Disorders
Central Nervous System
Repeats
Onset
Mental Retardation
Therapy

Keywords

  • Fragile X mental retardation gene (FMR1)
  • Fragile X mental retardation protein (FMRP)
  • Fragile X premutation (PM)
  • FXTAS
  • intranuclear inclusions

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuropsychology and Physiological Psychology
  • Clinical Psychology
  • Arts and Humanities (miscellaneous)
  • Developmental and Educational Psychology

Cite this

What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome? / Foote, Molly M.; Careaga, Milo; Berman, Robert F.

In: Clinical Neuropsychologist, Vol. 30, No. 6, 17.08.2016, p. 960-972.

Research output: Contribution to journalArticle

@article{d5548995f0a64a9eb4567b94cf076d56,
title = "What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?",
abstract = "Objective: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. Conclusions: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.",
keywords = "Fragile X mental retardation gene (FMR1), Fragile X mental retardation protein (FMRP), Fragile X premutation (PM), FXTAS, intranuclear inclusions",
author = "Foote, {Molly M.} and Milo Careaga and Berman, {Robert F}",
year = "2016",
month = "8",
day = "17",
doi = "10.1080/13854046.2016.1158254",
language = "English (US)",
volume = "30",
pages = "960--972",
journal = "Clinical Neuropsychologist",
issn = "1385-4046",
publisher = "Swets & Zeitlinger",
number = "6",

}

TY - JOUR

T1 - What has been learned from mouse models of the Fragile X Premutation and Fragile X-associated tremor/ataxia syndrome?

AU - Foote, Molly M.

AU - Careaga, Milo

AU - Berman, Robert F

PY - 2016/8/17

Y1 - 2016/8/17

N2 - Objective: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. Conclusions: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.

AB - Objective: To describe in this review how research using mouse models developed to study the Fragile X premutation (PM) and Fragile X-associated tremor/ataxia syndrome (FXTAS) have contributed to understanding these disorders. PM carriers bear an expanded CGG trinucleotide repeat on the Fragile X Mental Retardation 1 (FMR1) gene, and are at risk for developing the late onset neurodegenerative disorder FXTAS. Conclusions: Much has been learned about these genetic disorders from the development and study of mouse models. This includes new insights into the early cellular and molecular events that occur in PM carriers and in FXTAS, the presence of multiorgan pathology beyond the CNS, immunological dysregulation, unexpected synthesis of a potentially toxic peptide in FXTAS (i.e., FMRpolyG), and evidence that the disease process may be halted or reversed by appropriate molecular therapies given early in the course of disease.

KW - Fragile X mental retardation gene (FMR1)

KW - Fragile X mental retardation protein (FMRP)

KW - Fragile X premutation (PM)

KW - FXTAS

KW - intranuclear inclusions

UR - http://www.scopus.com/inward/record.url?scp=84976347020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976347020&partnerID=8YFLogxK

U2 - 10.1080/13854046.2016.1158254

DO - 10.1080/13854046.2016.1158254

M3 - Article

C2 - 27355912

AN - SCOPUS:84976347020

VL - 30

SP - 960

EP - 972

JO - Clinical Neuropsychologist

JF - Clinical Neuropsychologist

SN - 1385-4046

IS - 6

ER -